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It should be noted that not all of the inter-
actions between the slit diaphragm pro-
teins and the cytoskeleton are regulated 
by phosphorylation. For example, nephrin 
and NEPH1 associate with CD2AP and 
ZO1, respectively, both of which are pro-
teins associating with actin (Figure 1) (for 
references, see Johnstone and Holzman2), 
and phosphorylation-dependent regula-
tory mechanisms have not been identi-
ﬁed for these interactions thus far. Thus 
the nephrin–NEPH1 protein complex 
has multiple ways to associate with and 
regulate the actin cytoskeleton. Further 
studies using cell culture and especially 
animal models are necessary to deﬁne the 
cooperative functions of the slit diaphragm 
protein complexes.
Finally, the key task is to define the 
molecular mechanisms regulating podo-
cyte actin dynamics during development 
of podocyte injury and proteinuria in var-
ious human glomerular diseases. Uchida 
et al. analyzed by immunoﬂuorescence 
microscopy seven minimal-change neph-
rosis patients for the presence of tyrosine-
phosphorylated nephrin in podocytes 
and found that the level of nephrin Y1228 
phosphorylation was signiﬁcantly lower 
than in control patients.3 Although the 
patient number was quite small, the 
result, together with studies on animal 
models and cultured cells, supports a 
role for the nephrin protein complex not 
only as a structural component of the 
slit diaphragm structure, but also as an 
active signaling scaﬀold modulating the 
structural and functional characteristics 
of podocytes. A further challenge will be 
to deﬁne the molecular mechanisms and 
signals from within the podocyte that 
regulate ligand engagement and func-
tional behavior of the slit diaphragm 
proteins.
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The treatment of acute interstitial 
nephritis: More data at last
GB Appel1
Acute interstitial nephritis (AIN) is an uncommon form of acute renal 
failure that is usually medication related. Although the clinical features 
and renal histopathology are well recognized, therapy beyond 
discontinuing the offending drug has been a challenge. The use of 
corticosteroids, although supported by numerous small retrospective 
studies and anecdotal case reports, has been controversial. The study by 
González et al., although it has limitations, provides solid support for the 
early use of corticosteroids in the treatment of drug-related AIN.
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Although the spectrum of acute interstitial 
nephritis (AIN) encompasses many enti-
ties, including sarcoidosis, tubulointerstitial 
nephritis and uveitis syndrome, lupus, and 
other autoimmune interstitial nephritides, 
medication-related AIN remains the most 
common and clinically relevant form 
in native kidneys.1–3 Although numer-
ous medications have been incriminated, 
methicillin and other β-lactam antibiot-
ics were the prototype oﬀending agents 
for many years.3 Studies documented an 
epidemiologic relationship between the 
renal lesion and the penicillin, there were 
cases with recurrence on rechallenge, and 
remissions of the clinical disease occurred 
when the offending agent was stopped. 
The classic clinical triad of rash, fever, and 
eosinophilia in a patient with acute renal 
failure, especially if non-oliguric, would 
prompt a search for urinary eosinophils 
and a discontinuation of methicillin or 
any other potential offending medica-
tion.3 Recent studies document that the full 
hypersensitivity triad is not often present, 
and suspicion of AIN must be present 
with any of these features in a patient with 
renal failure on suspect medications.1–4 
When nonsteroidal anti-inflammatory 
drugs (NSAIDs) were reported to have 
unique clinical features, such as onset of 
the nephrotic syndrome, in association 
with acute renal failure and AIN, this was 
rapidly absorbed by clinicians.3 Thus, clini-
cal criteria for medication-induced AIN 
have been established for years. Likewise, 
nephropathologists have become adept at 
diagnosing AIN and even predicting medi-
cations as the etiology of the AIN by noting 
not only ‘tubulitis,’ but eosinophilic inﬁl-
trates and at times granulomatous changes 
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(Figure 1).3,5 The problem for the clinician 
has been therapy for this lesion.
In some anecdotal cases and brief series, 
addition of high-dose corticosteroids has 
led to dramatic improvement in the acute 
renal failure and return of renal function to 
almost baseline.2,3 However, skeptics can 
show equally impressive results in anecdo-
tal cases and small series with just discon-
tinuation of the medication alone.2–4 The 
debate is not trivial, as patients are often 
severely ill with their underlying infec-
tious and other medical conditions as well 
as the superimposed renal failure. Adding 
the potential risk of immunosuppression 
with corticosteroids is a major clinical deci-
sion far greater than just discontinuing or 
replacing the potential oﬀending drug.
If there were solid data from controlled 
randomized trials, the answer to two cru-
cial questions might be apparent. The ﬁrst 
question deals with speed and complete-
ness of clinical recovery from the acute 
renal failure. Prolonged renal failure surely 
increases risks for morbidity and mortal-
ity.3,7 The second question deals with the 
pathogenesis of the lesions. At what stage 
does the inﬂammatory inﬁltrate lead to 
interstitial ﬁbrosis and irreversible dam-
age?7,8 Although not always apparent 
immediately after the episode of acute 
renal failure resolves, this residual dam-
age may relate to chronic kidney disease, 
hypertension, and other adverse eﬀects 
years later. The question, then, is why 
there are no large controlled randomized 
trials to guide us here.
The answer is multifactorial. First, AIN 
is a relatively uncommon form of acute 
renal failure. Only a small minority of 
patients with acute renal failure come to 
renal biopsy, and even here, only a small 
proportion of biopsied patients have AIN. 
No single center can easily perform the 
large randomized trial necessary to give 
us the answers to those pressing ques-
tions. Second, many cases of AIN never 
come to biopsy. The diagnosis seems ﬁrm 
on clinical grounds, the oﬀending agent 
is stopped, and the patient recovers from 
the acute renal failure. How many of these 
patients truly would have AIN on biopsy 
is never known. Even in clear clinical cases 
the oﬀending drug may not be clear, with 
multiple potential agents that may cause 
AIN discontinued at the same time. A third 
problem is the concept of randomization to 
diﬀerent therapeutic strategies. It is easier 
for clinicians to randomize patients to two 
active currently used treatment regimens 
for lupus nephritis, than to delegate their 
patients to placebo versus corticosteroids. 
There are also few reports of alternate ther-
apies for AIN other than corticosteroids.9 
Some clinicians already have preconceived 
thoughts on whether corticosteroids are 
the optimal therapy for a given patient at 
a given time and do not feel it is ethical to 
use placebo in one arm of a study. Finally, 
how is long-term benefit to be proved? 
Only rarely is a group of AIN patients fol-
lowed long enough to check for changes in 
residual renal function. Even less common 
is the use of repeat biopsy to check for the 
development of renal interstitial ﬁbrosis. 
Such a biopsy would rarely contribute to a 
change in therapy of an individual patient 
but might provide tremendously valuable 
information for therapeutic intervention 
for others in the future.
Given these outstanding questions and 
problems with the ideal study design, the 
clinician still needs additional data to treat 
his or her patient appropriately. The study 
by González et al.10 (this issue) provides 
some of those data. This is a multicenter 
retrospective study of the influence of 
corticosteroids in 61 patients with biopsy-
proven AIN. As in many series, antibiotics 
and NSAIDs were the two primary oﬀend-
ing classes of drugs, comprising 93% of the 
patients. The majority of patients (52/61) 
received corticosteroids and experienced 
a signiﬁcantly lower serum creatinine as 
well as recovery and ability to discontinue 
dialysis. Of great interest is that the cor-
ticosteroid-treated patients who showed 
a complete return to baseline serum cre-
atinine, although similar at baseline to 
those who did not fully recover, diﬀered 
in time of onset of corticosteroid therapy. 
An earlier onset of use of corticosteroids 
after discontinuing the oﬀending drug (13 
versus 34 days) was associated with a bet-
ter recovery of renal function. The etiology 
of the medication-related AIN (antibiotic 
versus NSAID) did not appear to inﬂuence 
the outcome.
This study provides valuable informa-
tion but is far from conclusive. It is still 
small in numbers and retrospective in 
nature. What proportion of all clinically 
diagnosed AIN with acute renal failure 
it applies to is unknown. Does it apply to 
drug classes other than antibiotics and 
NSAIDs, such as the proton pump inhibi-
tors? Treatment with corticosteroids was 
not uniform as regards dose and duration 
of therapy. Repeat biopsies were done in 
only a handful of patients. Nevertheless, 
a clear message is available to the clini-
cian. At the time of discontinuation of the 
Figure 1 | Low-power micrograph (hematoxylin and eosin) showing inflammatory interstitial 
infiltrate in medication-induced acute interstitial nephritis. Tubular architecture is focally 
obliterated by infiltrate.
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putative oﬀending medication, the use of 
corticosteroids should be considered in 
all patients with AIN. This consideration 
should take into account not only rapidity 
and completeness of return of renal func-
tion to normal but also potential long-term 
beneﬁts in avoiding interstitial ﬁbrosis and 
eventual chronic kidney disease.
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Cardiac arrests in hemodialysis 
patients: An ongoing challenge
M Ostermann1
Hemodialysis patients have significant cardiac-related mortality. 
Sudden cardiac arrests in the dialysis unit are infrequent events 
but carry a poor prognosis. The predominant rhythm is ventricular 
tachycardia/fibrillation.  Although the exact etiologies are not clear, 
several studies have confirmed an increased incidence on the first day 
after the weekend interval.  Use of cardioprotective drugs and possibly 
an implantable cardioverter defibrillator may improve the prognosis of 
survivors after a cardiac arrest.  More research is needed in this field.
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Dialysis patients have an incidence 
of cardiac-related death 10–20 times 
higher than that of the general popu-
lation.1 They are particularly vulner-
able to a sudden cardiac arrest. In the 
Hemodialysis (HEMO) Study2 and Die 
Deutsche Diabetes Dialyse Studie (4D),3 
sudden death accounted for 25% of the 
observed total mortality. Analysis of the 
United States Renal Data System data-
base showed similar results: between 
2001 and 2003, 32% of all deaths 
among hemodialysis patients were due 
to sudden in- or out-of-hospital car-
diac arrests.4 Interestingly, this risk was 
high in the ﬁrst 6 months after starting 
dialysis, dropped to its lowest point by 
6 months, and then progressively rose 
again with each year on dialysis. Data 
from the System Case Mix Adequacy 
Study of the United States Renal Data 
System show that the proportion of sud-
den deaths in hemodialysis patients was 
signiﬁcantly higher on Mondays and 
Tuesdays compared with other days.5 
No other risk factors were identiﬁed. 
In a separate study, the same authors 
found a threefold increased risk of sud-
den cardiac arrest in the 12 hours before 
hemodialysis at the end of the weekend 
interval (Figure 1).6 The exact reasons 
for this phenomenon are not clear, but 
accumulation of ﬂuid and electrolytes 
may potentially play a role.
Cardiac arrests in the dialysis unit are 
relatively rare events but carry a poor 
prognosis. Karnik et al. showed a fre-
quency of 7 cardiac arrests per 100,000 
hemodialysis sessions.7 Affected 
patients were older, more likely to have 
diabetes, and more likely to dialyze via 
a catheter than the general hemodialysis 
population. Eighty-one percent of car-
diac arrests occurred while the patient 
was on dialysis. The vast majority of 
patients had no overt symptoms prior 
to the event. An abnormal rhythm was 
documented in only 17% of patients, 
with ventricular ﬁbrillation/tachycar-
dia being the predominant one (62%). 
Again, cardiac arrests were more fre-
quent on Mondays than on other days. It 
was also noted that 37% of patients had 
been hospitalized within the previous 30 
days, but there were no data on recent 
laboratory results, changes in medica-
tion, or reason for hospital admission. 
Outcome was poor: 60% of patients died 
within 48 hours of the arrest.
Pun et al. showed that traditional 
risk factors, including cardiovascular 
comorbidities, diabetes, hemoglobin, 
and dialysis adequacy, did not predict 
prognosis in hemodialysis patients after 
a cardiac arrest.8 Only use of β-blockers, 
calcium-channel blockers, angiotensin-
converting enzyme inhibitors, and angio-
tensin receptor blockers at the time of 
the event was signiﬁcantly associated 
with a better outcome. According to 
data from Herzog et al., dialysis patients 
who survive a cardiac arrest may also 
beneﬁt from an implantable cardioverter 
deﬁbrillator (ICD).9 In this retrospec-
tive cohort study, dialysis patients with 
an ICD after a cardiac arrest had a 42% 
reduction in mortality compared with 
